BioCentury | Oct 13, 2017
Product Development

Eyeing complement data

Clinical studies of four complement inhibitors in patients with age-related macular degeneration suggest the best target in the pathway may be complement 3 . However, differences between study populations and methods and durations of treatment also...
BC Innovations | Apr 10, 2014
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Meningitis; pneumonia Properdin Mouse studies suggest recombinant properdin could help protect against bacterial meningitis and pneumonia. In mice, intraperitoneal injection of recombinant properdin prior...
BC Innovations | Apr 10, 2014
Targets & Mechanisms

Positioning properdin

Researchers at the University of Leicester have shown that a recombinant properdin produced in collaboration with The Medicines Co. has markedly higher antibacterial activity than the native protein. 1 The researchers are now working to...
BC Innovations | Feb 16, 2012
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Aneurysm Properdin Studies in mice suggest inhibiting properdin could help treat abdominal aortic aneurysm. Properdin is a protein involved in...
BC Innovations | Sep 9, 2010
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Arthritis; autoimmune disease Properdin A study in mice suggests that inhibiting properdin could help treat autoimmune diseases such as arthritis. In a mouse...
BC Week In Review | Mar 17, 2003
Company News

Gliatech, Solentix BioSciences Inc. deal

CNS therapeutic developer Solentix plans to acquire GLIAQ’s IP and contracts related to its anti-inflammatory research, including patents for the complement protein properdin . The sale is part of GLIAQ’s previously announced bankruptcy proceedings (see BioCentury,...
BC Week In Review | Nov 5, 2001
Company News

Abgenix, Gliatech deal

ABGX received exclusive worldwide development and marketing rights to human monoclonal antibodies against complement protein properdin from GLIA for all indications, including cardiovascular and inflammatory diseases. Under a 2000 deal, ABGX used its XenoMouse technology...
BC Extra | Nov 2, 2001
Company News

ABGX, GLIA antibody deal

Abgenix (ABGX) received exclusive worldwide development and marketing rights to human monoclonal antibodies against complement protein properdin from Gliatech (GLIA) for all indications, including cardiovascular and inflammatory diseases. Under a 2000 deal, ABGX used its...
BC Week In Review | Oct 8, 2001
Clinical News

Anti-properdin agents regulatory update

GLIA received notice of allowance from the U.S. Patent and Trademark Office for claims covering the use of anti-properdin agents to inhibit inflammation. GLIA said it is developing antibodies to properdin, a protein of the...
BC Week In Review | Jul 31, 2000
Clinical News

Gliatech preclinical data

GLIA said that its antibody against properdin, a protein in the complement alternative pathway, reduced myocardial tissue damage in an animal model of heart attack. Data were presented at the International Complement Workshop in Snowbird....
Items per page:
1 - 10 of 15